Gain Therapeutics, Inc. (GANX) stock
GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.18+0.24 (+25.51%)
Close on Nov 17, 2026Market cap $51.50MP/E –Yield –
Gain Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Gain Therapeutics's operating margin for the twelve months ending Dec 31, 2023 was -40328.3%. For fiscal 2023 it was -40328.3%, against -12688.1% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -40328.3% | −27640.2 |
| FY2022 | Dec 31, 2022 | -12688.1% | −4308.3 |
| FY2021 | Dec 31, 2021 | -8379.8% | +3667.7 |
| FY2020 | Dec 31, 2020 | -12047.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2023 | Mar 31, 2023 | -9477.7% | +7475.8 |
| Q2 FY2022 | Jun 30, 2022 | -5443.0% | −1501.7 |
| Q1 FY2022 | Mar 31, 2022 | -7306.8% | +39512.7 |
| Q4 FY2021 | Dec 31, 2021 | -7426.3% | +10252.1 |
| Q3 FY2021 | Sep 30, 2021 | -16953.5% | −4721.0 |
| Q2 FY2021 | Jun 30, 2021 | -3941.3% | +4413.7 |
| Q1 FY2021 | Mar 31, 2021 | -46819.4% | −39142.8 |
| Q4 FY2020 | Dec 31, 2020 | -17678.5% | – |
| Q3 FY2020 | Sep 30, 2020 | -12232.5% | – |
| Q2 FY2020 | Jun 30, 2020 | -8355.0% | – |
| Q1 FY2020 | Mar 31, 2020 | -7676.6% | – |
See a number that looks wrong?